BACKGROUND: RGS17 and RGS20 encode two members of the regulator of G-protein signaling RGS-Rz subfamily. Variation in these genes may alter their transcription and thereby influence the function of G protein-coupled receptors, including opioid receptors, and modify risk for substance dependence. METHODS: The association of 13 RGS17 and eight RGS20 tag single nucleotide polymorphisms (SNPs) was examined with four substance dependence diagnoses (alcohol (AD), cocaine (CD), opioid (OD) or marijuana (MjD)] in 1,905 African Americans (AAs: 1,562 cases and 343 controls) and 1,332 European Americans (EAs: 981 cases and 351 controls). Analyses were performed using both χ2 tests and logistic regression analyses that covaried sex, age, and ancestry proportion. Correlation of genotypes and mRNA expression levels was assessed by linear regression analyses. RESULTS: Seven RGS17 SNPs showed a significant association with at least one of the four dependence traits after a permutation-based correction for multiple testing (0.003≤P(empirical)≤0.037). The G allele of SNP rs596359, in the RGS17 promoter region, was associated with AD, CD, OD, or MjD in both populations (0.005≤P(empirical)≤0.019). This allele was also associated with significantly lower mRNA expression levels of RGS17 in YRI subjects (P = 0.002) and non-significantly lower mRNA expression levels of RGS17 in CEU subjects (P = 0.185). No RGS20 SNPs were associated with any of the four dependence traits in either population. CONCLUSIONS: This study demonstrated that variation in RGS17 was associated with risk for substance dependence diagnoses in both AA and EA populations.
BACKGROUND:RGS17 and RGS20 encode two members of the regulator of G-protein signaling RGS-Rz subfamily. Variation in these genes may alter their transcription and thereby influence the function of G protein-coupled receptors, including opioid receptors, and modify risk for substance dependence. METHODS: The association of 13 RGS17 and eight RGS20 tag single nucleotide polymorphisms (SNPs) was examined with four substance dependence diagnoses (alcohol (AD), cocaine (CD), opioid (OD) or marijuana (MjD)] in 1,905 African Americans (AAs: 1,562 cases and 343 controls) and 1,332 European Americans (EAs: 981 cases and 351 controls). Analyses were performed using both χ2 tests and logistic regression analyses that covaried sex, age, and ancestry proportion. Correlation of genotypes and mRNA expression levels was assessed by linear regression analyses. RESULTS: Seven RGS17 SNPs showed a significant association with at least one of the four dependence traits after a permutation-based correction for multiple testing (0.003≤P(empirical)≤0.037). The G allele of SNP rs596359, in the RGS17 promoter region, was associated with AD, CD, OD, or MjD in both populations (0.005≤P(empirical)≤0.019). This allele was also associated with significantly lower mRNA expression levels of RGS17 in YRI subjects (P = 0.002) and non-significantly lower mRNA expression levels of RGS17 in CEU subjects (P = 0.185). No RGS20 SNPs were associated with any of the four dependence traits in either population. CONCLUSIONS: This study demonstrated that variation in RGS17 was associated with risk for substance dependence diagnoses in both AA and EA populations.
Authors: Seena K Ajit; Suneela Ramineni; Wade Edris; Rachel A Hunt; Wah-Tung Hum; John R Hepler; Kathleen H Young Journal: Cell Signal Date: 2006-10-07 Impact factor: 4.315
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: A Leygraf; C Hohoff; C Freitag; S A G Willis-Owen; P Krakowitzky; J Fritze; P Franke; B Bandelow; R Fimmers; J Flint; J Deckert Journal: J Neural Transm (Vienna) Date: 2006-06-01 Impact factor: 3.575
Authors: X Xuei; D Dick; L Flury-Wetherill; H-J Tian; A Agrawal; L Bierut; A Goate; K Bucholz; M Schuckit; J Nurnberger; J Tischfield; S Kuperman; B Porjesz; H Begleiter; T Foroud; H J Edenberg Journal: Mol Psychiatry Date: 2006-08-22 Impact factor: 15.992
Authors: Michael E Talkowski; Howard Seltman; Anne S Bassett; Linda M Brzustowicz; Xiangning Chen; Kodavali V Chowdari; David A Collier; Quirino Cordeiro; Aiden P Corvin; Smita N Deshpande; Michael F Egan; Michael Gill; Kenneth S Kendler; George Kirov; Leonard L Heston; Pat Levitt; David A Lewis; Tao Li; Karoly Mirnics; Derek W Morris; Nadine Norton; Michael C O'Donovan; Michael J Owen; Christian Richard; Prachi Semwal; Janet L Sobell; David St Clair; Richard E Straub; B K Thelma; Homero Vallada; Daniel R Weinberger; Nigel M Williams; Joel Wood; Feng Zhang; Bernie Devlin; Vishwajit L Nimgaonkar Journal: Biol Psychiatry Date: 2006-04-21 Impact factor: 13.382
Authors: Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Martha Michel; Denise Nishita; David V Conti; Christopher K Edlund; Pui-Yan Kwok; Jennifer B McClure; Richard B Kim; Sharon M Hall; Rachel F Tyndale; Timothy B Baker; Neal L Benowitz; Gary E Swan Journal: Nicotine Tob Res Date: 2014-08-20 Impact factor: 4.244
Authors: Katherine E Squires; Carolina Montañez-Miranda; Rushika R Pandya; Matthew P Torres; John R Hepler Journal: Pharmacol Rev Date: 2018-07 Impact factor: 25.468
Authors: G A Doyle; C L Schwebel; S E Ruiz; A D Chou; A T Lai; M-J Wang; G G Smith; R J Buono; W H Berrettini; T N Ferraro Journal: Neuroscience Date: 2014-07-22 Impact factor: 3.590
Authors: Laura R Lander; Vincent Setola; Shane W Kaski; Stephan Brooks; Sijin Wen; Marc W Haut; David P Siderovski; James H Berry Journal: J Opioid Manag Date: 2019 Mar-Apr
Authors: Johannes Thrul; Jill A Rabinowitz; Beth A Reboussin; Brion S Maher; Nicholas S Ialongo Journal: Addiction Date: 2020-07-21 Impact factor: 6.526